AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Proteolysis targeting chimeras (PROTACs) have recently emerged as promising therapeutic agents for cancer therapy. However, their clinical application is considerably hindered by the poor membrane permeability and insufficient tumor distribution of PROTACs. Here we proposed a nanoengineered targeting strategy to construct a self-assembled affibody-PROTAC conjugate nanomedicine (APCN) for tumor-specific delivery of PROTACs. As proof of concept, a hydrophobic PROTAC MZ1 (a bromodomain-containing protein 4 degrader) was selected to couple with a hydrophilic affibody ZHER2:342 (an affinity protein of human epidermal growth factor receptor 2, HER2) via a smart linker containing disulfide bond to form an amphiphilic ZHER2:342-MZ1 conjugate. It spontaneously self-assembled into nanoparticles (ZHER2:342-MZ1 APCN) in water. Upon the excellent targeting property of ZHER2:342 and HER2 receptor-mediated endocytosis, ZHER2:342-MZ1 APCN was accumulated in tumor sites and internalized by cancer cells effectively in vitro. Under the intracellular high level of glutathione (GSH), ZHER2:342-MZ1 APCN released MZ1 to specifically degrade bromodomain-containing protein 4 (BRD4) and subsequently induced BRD4 deficiency-mediated apoptosis of cancer cells. By the tail-vein injection, ZHER2:342-MZ1 APCN showed the outstanding tumor-specific targeting ability, drug accumulation capacity, enhanced BRD4 degradation and antitumor efficacy in vivo for an HER2-positive SKOV-3 tumor model. Such an affibody mediated nanoengineered strategy would facilitate the application of PROTACs for targeted cancer therapy.
Lai, A. C.; Crews, C. M. Induced protein degradation: An emerging drug discovery paradigm. Nat. Rev. Drug Discov. 2017, 16, 101–114.
Chamberlain, P. P.; Hamann, L. G. Development of targeted protein degradation therapeutics. Nat. Chem. Biol. 2019, 15, 937–944.
Gao, J.; Hou, B.; Zhu, Q. W.; Yang, L.; Jiang, X. Y.; Zou, Z. F.; Li, X. T.; Xu, T. F.; Zheng, M. Y.; Chen, Y. H. et al. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy. Nat. Commun. 2022, 13, 4318.
Popovic, D.; Vucic, D.; Dikic, I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 2014, 20, 1242–1253.
Burslem, G. M.; Crews, C. M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell 2020, 181, 102–114.
Dale, B.; Cheng, M.; Park, K. S.; Kaniskan, H. Ü.; Xiong, Y.; Jin, J. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 2021, 21, 638–654.
Paiva, S. L.; Crews, C. M. Targeted protein degradation: Elements of PROTAC design. Curr. Opin. Chem. Biol. 2019, 50, 111–119.
Chirnomas, D.; Hornberger, K. R.; Crews, C. M. Protein degraders enter the clinic—a new approach to cancer therapy. Nat. Rev. Clin. Oncol. 2023, 20, 265–278.
Edmondson, S. D.; Yang, B.; Fallan, C. Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges. Bioorg. Med. Chem. Lett. 2019, 29, 1555–1564.
Gu, S. S.; Cui, D. R.; Chen, X. Y.; Xiong, X. F.; Zhao, Y. C. PROTACs: An emerging targeting technique for protein degradation in drug discovery. Bioessays 2018, 40, 1700247.
Raina, K.; Crews, C. M. Targeted protein knockdown using small molecule degraders. Curr. Opin. Chem. Biol. 2017, 39, 46–53.
Cotton, A. D.; Nguyen, D. P.; Gramespacher, J. A.; Seiple, I. B.; Wells, J. A. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J. Am. Chem. Soc. 2021, 143, 593–598.
Dragovich, P. S.; Adhikari, P.; Blake, R. A.; Blaquiere, N.; Chen, J. H.; Cheng, Y. X.; den Besten, W.; Han, J. P.; Hartman, S. J.; He, J. T. et al. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα). Bioorg. Med. Chem. Lett. 2020, 30, 126907.
Dragovich, P. S.; Pillow, T. H.; Blake, R. A.; Sadowsky, J. D.; Adaligil, E.; Adhikari, P.; Bhakta, S.; Blaquiere, N.; Chen, J. H.; Dela Cruz-Chuh, J. et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: Exploration of antibody linker, payload loading, and payload molecular properties. J. Med. Chem. 2021, 64, 2534–2575.
Dragovich, P. S.; Pillow, T. H.; Blake, R. A.; Sadowsky, J. D.; Adaligil, E.; Adhikari, P.; Chen, J. H.; Corr, N.; Dela Cruz-Chuh, J.; Del Rosario, G. et al. Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: Improvement of in vitro antiproliferation activity and in vivo antitumor efficacy. J. Med. Chem. 2021, 64, 2576–2607.
Maneiro, M.; Forte, N.; Shchepinova, M. M.; Kounde, C. S.; Chudasama, V.; Baker, J. R.; Tate, E. W. Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4. ACS Chem. Biol. 2020, 15, 1306–1312.
Pillow, T. H.; Adhikari, P.; Blake, R. A.; Chen, J. H.; Del Rosario, G.; Deshmukh, G.; Figueroa, I.; Gascoigne, K. E.; Kamath, A. V.; Kaufman, S. et al. Antibody conjugation of a chimeric BET degrader enables activity. Chemmedchem 2020, 15, 17–25.
Chen, H.; Liu, J.; Kaniskan, H. Ü.; Wei, W. Y.; Jin, J. Folate-guided protein degradation by immunomodulatory imide drug-based molecular glues and proteolysis targeting chimeras. J. Med. Chem. 2021, 64, 12273–12285.
Liu, J.; Chen, H.; Liu, Y.; Shen, Y. D.; Meng, F. Y.; Kaniskan, H. Ü.; Jin, J.; Wei, W. Y. Cancer selective target degradation by folate-caged PROTACs. J. Am. Chem. Soc. 2021, 143, 7380–7387.
He, S. P.; Gao, F.; Ma, J. H.; Ma, H. Q.; Dong, G. Q.; Sheng, C. Q. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer. Angew. Chem., Int. Ed. 2021, 60, 23299–23305.
Beck, A.; Goetsch, L.; Dumontet, C.; Corvaïa, N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discov. 2017, 16, 315–337.
Li, Z.; Krippendorff, B. F.; Shah, D. K. Influence of Molecular size on the clearance of antibody fragments. Pharm. Res. 2017, 34, 2131–2141.
Liu, H. J.; Chen, W.; Wu, G. W.; Zhou, J.; Liu, C.; Tang, Z. M.; Huang, X. G.; Gao, J. J.; Xiao, Y. F.; Kong, N. et al. Glutathione-scavenging nanoparticle-mediated PROTACs delivery for targeted protein degradation and amplified antitumor effects. Adv. Sci. 2023, 10, 2207439.
Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Controlled Release 2000, 65, 271–284.
Yang, T. T.; Hu, Y. Z.; Miao, J. M.; Chen, J.; Liu, J. G.; Cheng, Y. Z.; Gao, X. A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization. Acta Pharm. Sin. B 2022, 12, 2658–2671.
Zhang, H. T.; Peng, R.; Chen, S.; Shen, A.; Zhao, L. X.; Tang, W.; Wang, X. H.; Li, Z. Y.; Zha, Z. G.; Yi, M. M. et al. Versatile nano-PROTAC-induced epigenetic reader degradation for efficient lung cancer therapy. Adv. Sci. 2022, 9, 2202039.
Grodzinski, P.; Farrell, D. Future opportunities in cancer nanotechnology-NCI strategic workshop report. Cancer Res. 2014, 74, 1307–1310.
Su, H.; Koo, J. M.; Cui, H. G. One-component nanomedicine. J. Controlled Release 2015, 219, 383–395.
Löfblom, J.; Feldwisch, J.; Tolmachev, V.; Carlsson, J.; Ståhl, S.; Frejd, F. Y. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 584, 2670–2680.
Nord, K.; Gunneriusson, E.; Ringdahl, J.; Ståhl, S.; Uhlén, M.; Nygren, P. Å. Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat. Biotechnol. 1997, 15, 772–777.
Ståhl, S.; Gräslund, T.; Karlström, A. E.; Frejd, F. Y.; Nygren, P. Å.; Löfblom, J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017, 35, 691–712.
Orlova, A.; Magnusson, M.; Eriksson, T. L. J.; Nilsson, M.; Larsson, B.; Höidén-Guthenberg, I.; Widström, C.; Carlsson, J.; Tolmachev, V.;Ståhl, S. et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006, 66, 4339–4348.
Persson, J.; Puuvuori, E.; Zhang, B.; Velikyan, I.; Åberg, O.; Müller, M.; Nygren, P. Å.; Ståhl, S.; Korsgren, O.; Eriksson, O. et al. Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69. Sci. Rep. 2021, 11, 19151.
Sörensen, J.; Sandberg, D.; Sandström, M.; Wennborg, A.; Feldwisch, J.; Tolmachev, V.; Åström, G.; Lubberink, M.; Garske-Román, U.; Carlsson, J. et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J. Nucl. Med. 2014, 55, 730–735.
Lindgren, J.; Ekblad, C.; Abrahmsén, L.; Karlström, A. E. A native chemical ligation approach for combinatorial assembly of affibody molecules. ChemBioChem 2012, 13, 1024–1031.
Perols, A.; Honarvar, H.; Strand, J.; Selvaraju, R.; Orlova, A.; Karlström, A. E.; Tolmachev, V. Influence of DOTA chelator position on biodistribution and targeting properties of 111In-Labeled synthetic Anti-HER2 affibody molecules. Bioconjugate Chem. 2012, 23, 1661–1670.
Xia, X. L.; Yang, X. Y.; Huang, W.; Xia, X. X.; Yan, D. Y. Self-assembled nanomicelles of affibody-drug conjugate with excellent therapeutic property to cure ovary and breast cancers. Nano-Micro Lett. 2022, 14, 33.
Yang, X. Y.; Xia, X. L.; Huang, W.; Xia, X. X.; Yan, D. Y. Highly efficient tumor-targeted nanomedicine assembled from affibody-drug conjugate for colorectal cancer therapy. Nano Res. 2023, 16, 5256–5264.
Yang, X. Y.; Xia, X. L.; Xia, X. X.; Sun, Z.; Yan, D. Y. Improving targeted delivery and antitumor efficacy with engineered tumor necrosis factor-related apoptosis ligand-affibody fusion protein. Mol. Pharmaceutics 2021, 18, 3854–3861.
Min, J. H.; Yang, H. F.; Ivan, M.; Gertler, F.; Kaelin, W. G.; Pavletich, N. P. Structure of an HIF-1α-pVHL complex: Hydroxyproline recognition in signaling. Science 2002, 296, 1886–1889.
Borck, P. C.; Guo, L. W.; Plutzky, J. BET epigenetic reader proteins in cardiovascular transcriptional programs. Circ. Res. 2020, 126, 1190–1208.
Liu, J. Y.; Duan, Z. B.; Guo, W. J.; Zeng, L.; Wu, Y. D.; Chen, Y. L.; Tai, F.; Wang, Y. F.; Lin, Y. W.; Zhang, Q. et al. Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Nat. Commun. 2018, 9, 5200.
Qian, H. H.; Zhu, M.; Tan, X. Y.; Zhang, Y. X.; Liu, X. N.; Yang, L. Super-enhancers and the super-enhancer reader BRD4: Tumorigenic factors and therapeutic targets. Cell Death Discov. 2023, 9, 470.
Raina, K.; Lu, J.; Qian, Y. M.; Altieri, M.; Gordon, D.; Rossi, A. M. K.; Wang, J.; Chen, X.; Dong, H. Q.; Siu, K. et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 2016, 113, 7124–7129.
Poon, W.; Zhang, Y. N.; Ouyang, B.; Kingston, B. R.; Wu, J. L. Y.; Wilhelm, S.; Chan, W. C. W. Elimination pathways of nanoparticles. ACS Nano 2019, 13, 5785–5798.
